Having trouble accessing articles? Reset your cache.

HepaRegeniX aims to bring liver program into clinic with €11M insider round

Existing investors back German academic spinout as its first-in-class molecule nears the clinic

With €11 million ($12.2 million) in fresh series B funding from insiders, liver regeneration company HepaRegeniX hopes to have a first-in-class molecule in the clinic by fall 2020.

Participating in the round were Boehringer Ingelheim Venture Fund, Novo Holdings A/S, High-Tech Gründerfonds,

Read the full 418 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE